



US009408848B2

(12) **United States Patent**  
**Yenugonda et al.**

(10) **Patent No.:** **US 9,408,848 B2**  
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER**

(75) Inventors: **Venkata Mahidhar Yenugonda**,  
McLean, VA (US); **Milton L. Brown**,  
Brookeville, MD (US)

(73) Assignee: **Georgetown University**, Washington,  
DC (US)

(\* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 344 days.

(21) Appl. No.: **13/059,180**

(22) PCT Filed: **Aug. 17, 2009**

(86) PCT No.: **PCT/US2009/054093**

§ 371 (c)(1),  
(2), (4) Date: **May 6, 2011**

(87) PCT Pub. No.: **WO2010/019967**

PCT Pub. Date: **Feb. 18, 2010**

(65) **Prior Publication Data**

US 2011/0269178 A1 Nov. 3, 2011

**Related U.S. Application Data**

(60) Provisional application No. 61/089,500, filed on Aug.  
15, 2008.

(51) **Int. Cl.**

**C12Q 1/34** (2006.01)  
**A61K 31/52** (2006.01)  
**A61K 31/4164** (2006.01)  
**A61K 49/00** (2006.01)  
**C07D 209/14** (2006.01)  
**C07D 233/72** (2006.01)  
**C07D 317/26** (2006.01)  
**C07D 473/16** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/52** (2013.01); **A61K 31/4164**  
(2013.01); **A61K 49/0021** (2013.01); **A61K**  
**49/0052** (2013.01); **C07D 209/14** (2013.01);  
**C07D 233/72** (2013.01); **C07D 317/26**  
(2013.01); **C07D 473/16** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61K 31/52**; **A61K 31/4164**; **A61K**  
**49/0021**; **A61K 49/0052**; **C07D 209/14**;  
**C07D 317/26**; **C07D 473/16**  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,274,082 A \* 12/1993 Seri et al. .... 534/16  
6,294,667 B1 9/2001 Jackson  
6,573,044 B1 \* 6/2003 Gray et al. .... 506/10  
2002/0016329 A1 \* 2/2002 Imbach et al. .... 514/261

2002/0146371 A1 \* 10/2002 Li et al. .... 424/1.73  
2002/0156277 A1 10/2002 Fick  
2003/0092565 A1 5/2003 Chaudhari  
2003/0176677 A1 9/2003 Lin  
2004/0034224 A1 2/2004 Hammarstrom  
2005/0009846 A1 1/2005 Fischer  
2005/0124808 A1 6/2005 Miller  
2005/0153371 A1 \* 7/2005 Grotzfeld et al. .... 435/7.5  
2006/0229330 A1 10/2006 Bartkovitz  
2007/0049603 A1 3/2007 Miknis

**FOREIGN PATENT DOCUMENTS**

GB 2334578 A \* 8/1999  
WO 9934018 7/1999  
WO WO 02076402 A2 \* 10/2002  
WO 03002565 1/2003  
WO WO 2007064759 A2 \* 6/2007

**OTHER PUBLICATIONS**

Rosania et al. Proc. natl. Acad. Sci. USA (1999) 96: 4797-4802.\*  
Knockaert et al. Chem. Biol. (2000) 7: 411-422.\*  
Defintion of composition downloaded from www.dictionary.com/  
browse/composition on Dec. 26, 2014.\*  
Chang, et al., "Synthesis and application of functionally diverse  
2,6,9-trisubstituted purine libraries as CDK inhibitors", Chem. Biol.,  
6:361-75 (1999).  
Chu, et al., "Discovery of [4-Amino-2-(1-methanesulfonyl)peridin-  
4-ylamino]pyrimidin-5,yl](2,3-difluoro-6-  
methoxyphenyl)methanone (R547), a potent and selective cyclin-  
dependent kinase inhibitor with significant in vivo antitumor  
activity", J. Med. Chem., 49:6549-60 (2006).  
Cohen, et al., "Monitoring of chemotherapy-induced cell death in  
melanoma tumors by N,N'-Didansyl-L-cystine", Cancer Res. Treat.,  
6:221-34 (2007).  
Collins and Garrett, "Targeting the cell division cycle in cancer: CDK  
and cell cycle checkpoint kinase inhibitors", Curr. Opin. Pharmacol.,  
5:366-73 (2005).  
Damianovich, et al., "ApoSense: a novel technology for functional  
molecular imaging of cell death in models of acute renal tubular  
necrosis", Eur J. Nucl. Med., 33:281-91 (2006).  
Davies, et al., "Structure-based design of a potent purine-based  
cyclin-dependent kinase inhibitor", Nat. Struct. Biol., 9:745-49  
(2002).  
Davies, et al., "Structure-based design of cyclin-dependent kinase  
inhibitors", Pharmacol Ther., 93:125-133 (2002).  
Gray, et al., "Exploiting chemical libraries, structure, and genomics  
in the search for kinase inhibitors", Science, 281:533-38 (1998).  
Harper and Elledge, "CDK inhibitors in development and cancer",  
Curr. Opin. Genet Dev., 6:56-64 (1996).  
Huwe, et al., Small molecules as inhibitors of cyclin-dependent  
kinases Angew Chem. Int. Ed. Engl., 42:2122-38 (2003).  
Knockaert, et al., "Pharmacological inhibitors of cyclin-dependent  
kinases", Trends Pharmacol Sci., 23:417-25 (2002).  
Morgan, "Cyclin-dependent kinases: engines, clocks, and micropro-  
cessors", Annu. Rev Cell Dev. Biol., 13:261-91 (1997).

(Continued)

*Primary Examiner* — Susan Hanley

(74) *Attorney, Agent, or Firm* — Pabst Patent Group LLP

(57) **ABSTRACT**

Disclosed are molecules and their synthesis. The fluorescent  
moiety also facilitates screening, tracking, and pharmacody-  
namic studies of the drug in a biological system both in vitro  
and in vivo.

**17 Claims, 9 Drawing Sheets**